Aardvark Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aardvark Therapeutics (AARD).

Price Target Range — 8 Quarters

Analyst Consensus — 11 Analysts

6Buy

4Hold

1Sell

Consensus RatingBuy# Analysts11Avg. Consensus PT$10Upside to Avg. PT+566.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 27, 2026	Jones Trading	Catherine Novack	PT Cut	Buy	$19→$10
Oct 26, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Neutral	$4→$2
Oct 19, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Neutral	$6→$4
Oct 12, 2026	BTIG	Jeet Mukherjee	Suspends	Neutral	—
Sep 24, 2026	RBC Capital	Brian Abrahams	Maintained	Sector Perform	$6
Jul 20, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Neutral	$6
May 15, 2026	B. Riley Securities	William Woods	PT Cut	Buy	$8→$7
May 15, 2026	BTIG	Jeet Mukherjee	Downgrade	Buy→Neutral	—
May 15, 2026	Morgan Stanley	Michael Ulz	Downgrade	Equal-Weight→Underweight	$7→$3
Mar 24, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$9
Mar 2, 2026	Oppenheimer	Leland Gershell	PT Cut	Outperform	$35→$21
Mar 2, 2026	BTIG	Jeet Mukherjee	PT Cut	Buy	$26→$9
Mar 2, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Downgrade	Buy→Neutral	—
Mar 2, 2026	Morgan Stanley	Michael Ulz	Downgrade	Overweight→Equal-Weight	$29→$7
Mar 2, 2026	Stifel	James Condulis	Downgrade	Buy→Hold	$24→$6
Mar 2, 2026	RBC Capital	Brian Abrahams	Downgrade	Outperform→Sector Perform	$18→$6
Feb 10, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$26
Feb 9, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$40
Dec 23, 2025	Oppenheimer	Leland Gershell	Initiate	Outperform	$35
Dec 12, 2025	William Blair	Andy Hsieh	Initiate	Outperform	—

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $2

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and lowers the price target from $4 to $2.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $4

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and lowers the price target from $6 to $4.

Benzinga Newsdesk

PRO
RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target

RBC Capital analyst Brian Abrahams reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Sector Perform and maintains $6 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and announces $6 price target.

Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7

B. Riley Securities analyst William Woods maintains Aardvark Therapeutics (NASDAQ:AARD) with a Buy and lowers the price target from $8 to $7.

Benzinga Newsdesk

This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Top Wall Street analysts changed outlook on top names. DA Davidson initiated coverage on EBC & UNTY with Buy ratings. See other analyst views.

Avi Kapoor

Aardvark Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Aardvark Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $2

PRO
HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $4

PRO
RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target

PRO
HC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price Target

PRO
B. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7

This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

People Also Watch

People Also Watch

Aardvark Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Aardvark Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $2

PROHC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $4

PRORBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target

PROHC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price Target

PROB. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7

This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $2

PRO
HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $4

PRO
RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target

PRO
HC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price Target

PRO
B. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7